Work

Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care

Year: 2025

Type: article

Abstract: Chronic myeloid leukemia (CML) has shifted from a fatal to a chronic disease with tyrosine kinase inhibitors (TKIs) [ 1 ]. Its prevalence, now 10−15 per 100,000, is rising, projected to plateau by 2050 at 35 times the annual incidence, making CML one of the most common hematologic malignancies [ 2 , 3 ]. Management is guided by international protocols, with adherence essential for optimizing outcomes and quality of life [ 4 , 5 ]. The main goal within 12 months of TKI-therapy is achieving major molecular response, followed by deep molecular response [ 6 ]. Emerging strategies like treatment-free remission (TFR) and dose reduction require strict guideline-based management to be effective. CML care is fragmented, posing risks to optimal monitoring and guideline adherence (GA), with unfavorable impact on outcomes [ 3 , 7 , 8 ]. GA in CML care is often suboptimal, and its impact on survival remains unclear. Quality indicators (QIs), measurable benchmarks from clinical guidelines, are used to assess adherence and care quality in practice [ 9 , 10 ]. Our study evaluates adherence to QIs and examines the impact of GA on overall survival (OS).

Source: Blood Cancer Journal

DOI: 10.1038/s41408-025-01423-5

Authors: Sanne J. J. P. M. Metsemakers, Geneviève I. C. G. Ector, Avinash G. Dinmohamed, Rosella P. M. G. Hermens, Nicole M. A. Blijlevens

Institutions: Radboud University Nijmegen, Radboud University Medical Center, Rijnstate Hospital, Netherlands Comprehensive Cancer Organisation

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,290